Journal guides › Fastest review journals › Oncology
Check the full review time of any journalMedian days, your chances within 3 or 6 months, the dates if you submit today and faster journals in the same subjects.
Quick answerAmong 125 journals in Oncology that publish their review dates, Anti-Cancer Drugs has the shortest review time: a median of 3 days from submission to acceptance.
| # | Journal | Median days | Spread of review times | Impact factor* | Indexed in | Access |
|---|---|---|---|---|---|---|
| 1 | Anti-Cancer Drugs | 3 | 1–33 | 2.23 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 2 | American Journal of Clinical Oncology | 4 | 2–14 | 1.58 | SCIE | Hybrid / subscription |
| 3 | Die Onkologie | 22 | 8–57 | 0.26 | SCIE | Hybrid / subscription |
| 4 | Journal of Neuro-Oncology | 41 | 33–55 | 3.16 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 5 | Current Breast Cancer Reports | 42 | 21–104 | 1.25 | ESCI, Scopus, JCR 2024 | Hybrid / subscription |
| 6 | Current Hematologic Malignancy Reports | 48 | 32–49 | 3.76 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 7 | Investigational New Drugs | 56 | 38–80 | 4.31 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 8 | Journal of Cancer Education | 59 | 28–94 | 1.26 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 9 | Current Treatment Options in Oncology | 59 | 34–113 | 6.71 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 10 | memo - Magazine of European Medical Oncology | 64 | 39–84 | 0.78 | ESCI, Scopus, JCR 2024 | Hybrid / subscription |
| 11 | CA A Cancer Journal for Clinicians | 65 | 35–93 | 228.9 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$4,330 |
| 12 | Radiation Oncology Journal | 66 | 39–92 | 1.79 | ESCI, Scopus, JCR 2024 | Open access |
| 13 | European Journal of Cancer Prevention | 66 | 50–90 | 2.73 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 14 | Journal of the Korean Gastric Cancer Association | 69 | 33–108 | 5.95 | SCIE | Hybrid / subscription |
| 15 | Oncology and Therapy | 70 | 49–105 | 2.50 | ESCI, Scopus, JCR 2024 | Open access · APC ~US$7,400 |
| 16 | Journal of Cancer Prevention | 70 | 31–92 | 2.05 | ESCI, JCR 2024 | Open access |
| 17 | Genes Chromosomes and Cancer | 71 | 43–103 | 1.73 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 18 | Pediatric Blood & Cancer | 73 | 34–122 | 1.54 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 19 | Cancer Cytopathology | 74 | 50–97 | 2.03 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 20 | Melanoma Research | 74 | 45–123 | 1.90 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 21 | Clinical & Translational Oncology | 76 | 48–117 | 2.72 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 22 | Expert Review of Anticancer Therapy | 77 | 54–102 | 2.90 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 23 | International Journal of Cancer Management | 77 | 40–126 | 0.67 | ESCI, Scopus, JCR 2024 | Open access |
| 24 | Anti-Cancer Agents in Medicinal Chemistry | 78 | 63–102 | 2.13 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 25 | International Journal of Surgery Oncology | 78 | 52–123 | 0.40 | ESCI, JCR 2024 | Hybrid / subscription |
| 26 | Journal of Hematology & Oncology | 80 | 60–104 | 35.4 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$4,990 |
| 27 | Annals of Surgical Oncology | 80 | 20–130 | 1.77 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 28 | Cancer Nursing | 80 | 8–156 | 1.85 | SCIE, SSCI, Scopus, JCR 2024 | Hybrid / subscription |
| 29 | Leukemia & lymphoma/Leukemia and lymphoma | 82 | 61–117 | 1.76 | SCIE | Hybrid / subscription |
| 30 | Infectious Agents and Cancer | 82 | 62–110 | 3.12 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$3,190 |
| 31 | Recent Patents on Anti-Cancer Drug Discovery | 86 | 63–110 | 1.77 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 32 | Gaceta Mexicana de Oncología | 86 | 44–129 | 0.10 | ESCI, Scopus, JCR 2024 | Open access |
| 33 | Current Cancer Therapy Reviews | 88 | 70–109 | 1.00 | ESCI, Scopus, JCR 2024 | Hybrid / subscription |
| 34 | Molecular & Cellular Oncology | 88 | 62–137 | 2.56 | ESCI, Scopus, JCR 2024 | Open access · APC ~US$1,590 |
| 35 | Gastric Cancer | 91 | 60–136 | 6.17 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 36 | Case Reports in Oncological Medicine | 92 | 65–153 | 0.49 | ESCI, Scopus, JCR 2024 | Open access · APC ~US$790 |
| 37 | Biomarker Research | 94 | 69–126 | 15.2 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$3,890 |
| 38 | Journal of Clinical Oncology | 94 | 37–160 | 1.86 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 39 | Journal of Cancer Survivorship | 96 | 72–147 | 3.23 | SCIE, SSCI, Scopus, JCR 2024 | Hybrid / subscription |
| 40 | Current Cancer Drug Targets | 96 | 76–116 | 1.98 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 41 | Cancer Nanotechnology | 96 | 67–136 | 6.70 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$1,990 |
| 42 | International Journal of Clinical Oncology | 97 | 64–129 | 2.88 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 43 | Molecular Cancer | 100 | 73–155 | 29.6 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$5,090 |
| 44 | Strahlentherapie und Onkologie | 100 | 53–140 | 2.43 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 45 | Targeted Oncology | 100 | 65–136 | 4.89 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 46 | World Journal of Surgical Oncology | 104 | 73–148 | 2.68 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$2,990 |
| 47 | Nutrition and Cancer | 104 | 64–158 | 2.81 | Scopus | Hybrid / subscription |
| 48 | Cancer | 104 | 71–151 | 4.54 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 49 | Breast Cancer Research and Treatment | 107 | 75–150 | 3.57 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 50 | Thoracic Cancer | 108 | 76–162 | 2.34 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$3,030 |
| 51 | Cancer Research and Treatment | 110 | 80–157 | 3.44 | SCIE, Scopus, JCR 2024 | Open access |
| 52 | Hereditary Cancer in Clinical Practice | 110 | 72–176 | 2.60 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$2,690 |
| 53 | Molecular Carcinogenesis | 111 | 70–154 | 3.14 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 54 | Cancer Chemotherapy and Pharmacology | 112 | 81–143 | 2.36 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 55 | Indian Journal of Surgical Oncology | 113 | 71–160 | 0.74 | ESCI, Scopus, JCR 2024 | Hybrid / subscription |
| 56 | Cardio-Oncology | 113 | 84–168 | 2.32 | ESCI, Scopus, JCR 2024 | Open access · APC ~US$2,790 |
| 57 | Experimental Hematology and Oncology | 114 | 77–167 | 14.3 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$3,290 |
| 58 | Journal of Chemotherapy | 114 | 84–160 | 2.47 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 59 | Familial Cancer | 114 | 76–156 | 2.52 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 60 | Hematological Oncology | 115 | 74–166 | 0.66 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 61 | Breast Cancer | 117 | 77–171 | 2.90 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 62 | Cancer Imaging | 118 | 77–175 | 5.34 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$2,790 |
| 63 | JCO Oncology Practice | 118 | 88–164 | 1.41 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 64 | Melanoma Management | 118 | 76–214 | 1.73 | ESCI, Scopus, JCR 2024 | Open access · APC ~US$1,415 |
| 65 | Blood Cancer Journal | 119 | 92–160 | 7.89 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$5,290 |
| 66 | Cancer Innovation | 119 | 79–179 | 3.84 | ESCI, Scopus | Open access · APC ~US$2,700 |
| 67 | Journal of Breast Cancer | 121 | 82–157 | 2.13 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$500 |
| 68 | Future Oncology | 122 | 83–181 | 2.95 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 69 | Bone Marrow Transplantation | 122 | 80–172 | 3.27 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 70 | MedComm – Oncology | 122 | 89–163 | 5.49 | ESCI, Scopus | Open access |
| 71 | OncoImmunology | 124 | 71–173 | 6.55 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$2,913 |
| 72 | Journal of Experimental & Clinical Cancer Research | 124 | 93–151 | 13.0 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$4,190 |
| 73 | Journal of Surgical Oncology | 125 | 88–184 | 2.08 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 74 | Cancer and Metastasis Reviews | 126 | 96–174 | 12.4 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 75 | JCO Global Oncology | 127 | 91–174 | 2.37 | ESCI, Scopus, JCR 2024 | Open access · APC ~US$2,472 |
| 76 | Prostate Cancer and Prostatic Diseases | 128 | 73–162 | 5.96 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 77 | Cancer Science | 128 | 84–163 | 4.42 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$2,600 |
| 78 | Journal of Immunotherapy | 129 | 79–180 | 2.19 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 79 | Cancer Causes & Control | 130 | 78–198 | 1.42 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 80 | Pediatric Hematology and Oncology | 130 | 85–160 | 1.19 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 81 | Pigment Cell & Melanoma Research | 132 | 74–194 | 3.22 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 82 | Cancer Biology & Therapy | 134 | 96–209 | 6.81 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$2,970 |
| 83 | Leukemia | 135 | 103–193 | 6.89 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 84 | Discover Oncology | 136 | 100–168 | 2.43 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$1,690 |
| 85 | JCO Precision Oncology | 136 | 97–184 | 3.45 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 86 | International Journal of Hyperthermia | 137 | 102–200 | 2.74 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$2,557 |
| 87 | Journal of Mammary Gland Biology and Neoplasia | 137 | 91–214 | 2.91 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 88 | Molecular Oncology | 140 | 95–192 | 3.48 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$4,300 |
| 89 | Breast Cancer Research | 142 | 105–193 | 5.80 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$4,190 |
| 90 | BMC Cancer | 143 | 92–265 | 3.95 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$3,390 |
| 91 | Clinical Epigenetics | 143 | 88–215 | 5.64 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$3,890 |
| 92 | Brain Tumor Pathology | 143 | 106–176 | 1.31 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 93 | Journal of the Egyptian National Cancer Institute | 148 | 86–242 | 2.25 | ESCI, Scopus, JCR 2024 | Open access |
| 94 | Cancer & Metabolism | 148 | 97–197 | 5.67 | SCIE, JCR 2024 | Open access · APC ~US$3,190 |
| 95 | JCO Clinical Cancer Informatics | 152 | 104–208 | 2.78 | ESCI, Scopus, JCR 2024 | Hybrid / subscription |
| 96 | Radiation Oncology | 153 | 105–223 | 3.60 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$3,290 |
| 97 | International Journal of Breast Cancer | 153 | 99–201 | 1.81 | ESCI, Scopus, JCR 2024 | Open access · APC ~US$1,000 |
| 98 | Journal of Pediatric Hematology/Oncology | 156 | 106–221 | 0.96 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 99 | International Journal of Cancer | 156 | 104–197 | 4.49 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 100 | Rehabilitation Oncology | 156 | 125–172 | 0.63 | ESCI, Scopus, JCR 2024 | Hybrid / subscription |
| 101 | Asia-Pacific Journal of Clinical Oncology | 161 | 93–287 | 1.04 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 102 | Cancer Investigation | 167 | 90–312 | 2.05 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 103 | Psycho-Oncology | 168 | 113–232 | 2.84 | SCIE, SSCI, Scopus, JCR 2024 | Hybrid / subscription |
| 104 | Journal of Cancer Research and Therapeutics | 169 | 99–260 | 1.56 | SCIE, Scopus, JCR 2024 | Open access |
| 105 | The Journal of Pathology | 172 | 122–231 | 3.73 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 106 | npj Breast Cancer | 174 | 112–234 | 6.19 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$3,790 |
| 107 | Cancer Gene Therapy | 177 | 134–234 | 7.36 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 108 | Oncogenesis | 178 | 128–227 | 4.36 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$4,290 |
| 109 | Hepatic Oncology | 185 | 149–209 | 2.71 | ESCI, Scopus, JCR 2024 | Open access · APC ~US$1,415 |
| 110 | European Journal of Cancer Care | 189 | 128–251 | 0.79 | SCIE, SSCI, Scopus, JCR 2024 | Hybrid / subscription |
| 111 | Supportive Care in Cancer | 190 | 145–243 | 2.03 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 112 | Prostate Cancer | 190 | 130–280 | 1.20 | ESCI, Scopus, JCR 2024 | Open access · APC ~US$1,000 |
| 113 | Journal of Gynecologic Oncology | 192 | 133–260 | 2.92 | SCIE, Scopus, JCR 2024 | Open access |
| 114 | Medical Oncology | 194 | 123–244 | 4.68 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 115 | Journal of Psychosocial Oncology Research and Practice | 194 | 136–265 | 1.12 | ESCI, Scopus | Open access |
| 116 | Colorectal Cancer | 194 | 152–230 | 1.27 | ESCI, JCR 2024 | Open access |
| 117 | Indian Journal of Cancer | 195 | 113–564 | 0.76 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 118 | Cancer Medicine | 197 | 125–272 | 3.87 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$4,700 |
| 119 | npj Precision Oncology | 202 | 140–268 | 9.01 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$4,090 |
| 120 | British Journal of Cancer | 205 | 158–272 | 6.96 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 121 | Oncogene | 212 | 160–258 | 6.78 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
| 122 | Cancer Reports | 218 | 156–284 | 1.58 | ESCI, Scopus, JCR 2024 | Open access · APC ~US$3,280 |
| 123 | Cancer Cell International | 224 | 170–299 | 6.49 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$3,190 |
| 124 | The Breast Journal | 243 | 155–362 | 1.73 | SCIE, Scopus, JCR 2024 | Open access · APC ~US$2,350 |
| 125 | Nature Cancer | 330 | 244–459 | 18.0 | SCIE, Scopus, JCR 2024 | Hybrid / subscription |
The box shows the middle half of each journal's papers and the dark line its median. *Impact factor: 2-year citedness from OpenAlex open data, not the official Clarivate value.
Want an expert to shortlist fast-review journals that match your manuscript? Journal Selection & Submission picks up to 5 journals for your paper and handles the submission. Avoid a rejection that adds months: a Manuscript Audit shows what reviewers will flag first.
Source, method and date. Source: the received and accepted dates that publishers deposit with each article in Crossref. Method: for each journal, the days from received to accepted for its research articles of the last 24 months (at least 10 articles), then the median; journals whose publisher does not deposit these dates are not listed. Updated: 28 October 2026, refreshed about every 3 months. Only accepted papers carry these dates, so rejections are not counted, and a journal may count from a different date. ScholarsColab is not affiliated with these journals.
Frequently asked questions
Which Oncology journals have the fastest review?
By median days from submission to acceptance: Anti-Cancer Drugs (3 days); American Journal of Clinical Oncology (4 days); Die Onkologie (22 days). Source: dates deposited by the publishers in Crossref, updated 28 October 2026.
Is a fast review journal in Oncology a good choice?
Review time is one factor. Check the journal’s scope, indexing and impact factor too, and confirm it is not predatory: a very short review with no real reviewer comments is a warning sign. Journal pages on ScholarsColab show all of these together.
Where do these review times come from?
From the received and accepted dates that publishers deposit in Crossref, the scholarly publication registry. ScholarsColab takes the median for each journal over its research articles of the last 24 months. Updated 28 October 2026.
Related: Journal Finder · Journal Directory · How to choose a journal · APC waiver checker